Reviewing Bausch + Lomb (NYSE:BLCO) and PACS Group (NYSE:PACS)

Bausch + Lomb (NYSE:BLCO) and PACS Group (NYSE:PACS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Earnings & Valuation

This table compares Bausch + Lomb and PACS Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$4.79 billion	1.13	-$317.00 million	($0.78)	-19.65
PACS Group	$3.11 billion	0.40	$112.87 million	N/A	N/A

PACS Group has lower revenue, but higher earnings than Bausch + Lomb.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bausch + Lomb and PACS Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1	7	3	0	2.18
PACS Group	0	1	5	0	2.83

Bausch + Lomb currently has a consensus price target of $15.56, indicating a potential upside of 1.50%. PACS Group has a consensus price target of $33.33, indicating a potential upside of 313.31%. Given PACS Group’s stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than Bausch + Lomb.

Profitability

This table compares Bausch + Lomb and PACS Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-5.58%	2.33%	1.12%
PACS Group	N/A	N/A	N/A

Institutional and Insider Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. 0.2% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Bausch + Lomb has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, PACS Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.